Abstract 1550
Background
There is scarce data of the impact of inflammatory indexes in locally advanced NSCLC, which is a highly heterogeneous illness. Choice of therapy is complex and often, combined CRT, either concurrently or sequentially is used. We aim to determine the impact of NLR monitoring in patients with stage III NSCLC treated with CRT.
Methods
Patients with stage III NSCLC treated with CRT were identified from Jan2010 to Dec2015 in our centre. NLR (neutrophils/lymphocytes) was retrospectively collected at baseline (B) and 5-6 weeks after CRT (C). It was considered a continuous variable and categorised (low <4, high ≥4). NLR monitoring (B and C) stratified 2 groups: good (NLR remained <4 and NLR decreased ≥4 to < 4) and poor (NLR increased <4 to ≥ 4 and NLR remained ≥4). Progression-free survival (PFS) and overall survival (OS) were estimated with Kaplan-Meier method and log-rank test. Cox regression model was used for the multivariate analysis.
Results
92 patients were included; median age 65.5 years (39-83); 85.87% were male and 90.3% had ECOG 0-1. Predominant histologies: adenocarcinoma (41.3%) and squamous-cell carcinoma (56.5%). Concurrent treatment in 78.9% patients and sequential in 21.1%. Median PFS and OS were 16.23 and 30.36 months (mo), in the overall population. On the multivariate analysis, the good prognostic group had significant longer median PFS and OS than the poor group: 33.9 vs 11.1 mo (p<.001) and 48.8 vs 17.4 mo (p<.001), respectively. Higher post-treatment NLR was also associated with shorter PFS and OS.Table:
1466P
Multivariate analysis | ||||
---|---|---|---|---|
PFS | OS | |||
HR (95% CI) | p value | HR (95% CI) | p value | |
ECOG | 1.65 (0.81 – 3.38) | 0.169 | 2.55 (1.17 – 5.56) | 0.018 |
Sequiential vs. Concurrent CRT | 0.87 (0.41 – 1.81) | 0.703 | 0.87 (0.38 – 1.97) | 0.732 |
Baseline NLR | 1.01 (0.83 – 1.23) | 0.918 | 0.84 (0.66 – 1.07) | 0.158 |
Post CRT NLR (low vs high) | 1.08 (1.01 – 1.15) | 0.018 | 1.11 (1.05 – 1.19) | <0.001 |
Prognostic groups (good vs poor) | 3.00 (1.49 – 6.02) | 0.002 | 2.83 (1.30 – 6.14) | 0.009 |
Conclusions
NLR could be used as a prognostic factor in stage III NSCLC especially when considering its dynamic evolution. Our results provide the opportunity to evaluate this inexpensive and reproducible index as a prognostic or predictive biomarker in prospective studies, particularly with the novel use of anti-PD-1/L1 after CRT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hospital Universitario Doctor Peset.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2459 - Does bevacizumab increase joint pain ? Preliminary results of BEVARTHRALGIA Study
Presenter: Vauleon Enora
Session: Poster Display session 1
Resources:
Abstract
4913 - Prostatic cancer androgen deprivation therapy and bone health in carcinoma prostate.
Presenter: Gouri Shankar Bhattacharyya
Session: Poster Display session 1
Resources:
Abstract
1352 - Patterns of care for patients with metastatic bone disease in solid tumors – a cross-sectional study (SAKK 95/16)
Presenter: Michael Mark
Session: Poster Display session 1
Resources:
Abstract
6002 - Infection-Related Mortality in Different Types of Cancers
Presenter: Mohamed Gouda
Session: Poster Display session 1
Resources:
Abstract
5643 - Survival Trends in Critically ill Oncology Patients: impact of patient’s eligibility to post-ICU chemotherapy
Presenter: Edith Borcoman
Session: Poster Display session 1
Resources:
Abstract
3097 - Development and validation of a multivariable prediction model for 6-month mortality in older cancer patients: the GeriAtrIc-Tumor Score of PrEdiction for Early Death (GAIT SPEED)
Presenter: Angeli Angeli
Session: Poster Display session 1
Resources:
Abstract
856 - A Longitudinal Tracking and Quantitative Assessment of Paclitaxel-Induced Peripheral Neurotoxicity
Presenter: Ayumu Matsuoka
Session: Poster Display session 1
Resources:
Abstract
1662 - Efficiency of controlled cryotherapy in prevention of chemotherapy induced peripheral neuropathy (CIPN)
Presenter: Trudi Schaper
Session: Poster Display session 1
Resources:
Abstract
2766 - The Validity of Evaluations for Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Presenter: Teppei Yamada
Session: Poster Display session 1
Resources:
Abstract
5683 - Prevention of chemoradiation-related mucositis in patients with head and neck cancer using dexamethasone-based mouthwash: A phase II randomized double-blind, placebo-controlled study
Presenter: Naiyarat Prasongsook
Session: Poster Display session 1
Resources:
Abstract